NASDAQ:TBPH - Theravance Biopharma Stock Price, Forecast & News

$25.77

-0.67 (-2.53 %)

(As of 01/23/2020 04:00 PM ET)

Add

Compare

Today's Range

$25.49

Now: $25.77▼

$26.64

50-Day Range

$20.72

MA: $23.95▼

$26.44

52-Week Range

$15.18

Now: $25.77▼

$28.44

Volume312,700 shs

Average Volume265,227 shs

Market Capitalization$1.46 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.85

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:TBPH

Previous SymbolNASDAQ:TBPHV

CUSIPN/A

CIK1583107

Webhttp://www.theravance.com/

Phone650-808-6000

Debt

Debt-to-Equity RatioN/A

Current Ratio3.27

Quick Ratio3.27

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$60.37 million

Price / Sales24.23

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.93) per share

Price / Book-27.71

Profitability

EPS (Most Recent Fiscal Year)($3.99)

Net Income$-215,520,000.00

Net Margins-370.54%

Return on EquityN/A

Return on Assets-43.57%

Miscellaneous

Employees363

Outstanding Shares56,762,000

Market Cap$1.46 billion

Next Earnings Date2/25/2020 (Estimated)

OptionableOptionable

Receive TBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.

(Ad)

In early 2019 President Trump warned this company's biggest customers to "step up their 5G efforts." A few months later, he banned their biggest competitor from doing business in the U.S. Now, this $5 stock could turn a $10,000 stake into $234,770 this year. But timing is critical. A single mention on the evening news and this opportunity could get away from you.

Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma Inc (NASDAQ:TBPH) released its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($1.05). The biopharmaceutical company earned $12.43 million during the quarter, compared to analysts' expectations of $13.33 million. View Theravance Biopharma's Earnings History.

When is Theravance Biopharma's next earnings date?

Theravance Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Theravance Biopharma.

What price target have analysts set for TBPH?

4 brokerages have issued 12 month price targets for Theravance Biopharma's shares. Their forecasts range from $18.00 to $55.00. On average, they anticipate Theravance Biopharma's share price to reach $35.75 in the next twelve months. This suggests a possible upside of 38.7% from the stock's current price. View Analyst Price Targets for Theravance Biopharma.

What is the consensus analysts' recommendation for Theravance Biopharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Theravance Biopharma.

What are Wall Street analysts saying about Theravance Biopharma stock?

Here are some recent quotes from research analysts about Theravance Biopharma stock:

1. Cantor Fitzgerald analysts commented, ". We believe it is a good time to take another look at TBPH given its inexpensive valuation, and ahead of important catalysts this year. We also note that TBPH’s cash and equivalents totaled $517.1MM as of 12/31/18. It appears well-positioned to receive over $1B in milestones and payments, but its market cap is only ~$1.3B. Therefore, we think the peak sales potential of TBPH’s organ-selective Trelegy, are all underappreciated. Our positive investment thesis supports our OW rating and 12-month PT of $55." (4/12/2019)
2. According to Zacks Investment Research, "Theravance reported narrower-than-expected loss in Q4. Also, revenues beat estimates. The company received a huge boost when the FDA approved Yupelri, the first once daily nebulized LAMA option for COPD, in November. Formal launch activities of Yupelri are currently underway. Meanwhile, the agreement to divest its only marketed drug, Vibativ, will enable Theravance to focus solely on the launch efforts of Yupelri. Moreover, its pipeline programs target highly competitive therapeutic areas. The company's collaboration agreements are a consistent source of funds. However, any agreement termination might be a huge setback for the company as was the case in the past. Shares of the company have underperformed the industry so far this year." (3/13/2019)

Has Theravance Biopharma been receiving favorable news coverage?

News stories about TBPH stock have been trending somewhat negative this week, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Theravance Biopharma earned a media sentiment score of -1.8 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Theravance Biopharma.

Are investors shorting Theravance Biopharma?

Theravance Biopharma saw a decline in short interest in December. As of December 31st, there was short interest totalling 2,640,000 shares, a decline of 5.4% from the December 15th total of 2,790,000 shares. Based on an average daily volume of 309,100 shares, the short-interest ratio is presently 8.5 days. Currently, 6.9% of the company's shares are short sold. View Theravance Biopharma's Current Options Chain.

Who are some of Theravance Biopharma's key competitors?

Some companies that are related to Theravance Biopharma include Ascendis Pharma A/S (ASND), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), BridgeBio Pharma (BBIO), Allakos (ALLK), United Therapeutics (UTHR), Nektar Therapeutics (NKTR), Blueprint Medicines (BPMC), FibroGen (FGEN), SAGE Therapeutics (SAGE), Mirati Therapeutics (MRTX), GW Pharmaceuticals PLC- (GWPH), Deciphera Pharmaceuticals (DCPH) and PTC Therapeutics (PTCT).

What other stocks do shareholders of Theravance Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Bausch Health Companies (BHC), Gilead Sciences (GILD), Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Immunomedics (IMMU), SCYNEXIS (SCYX), Johnson & Johnson (JNJ), Corbus Pharmaceuticals (CRBP), GW Pharmaceuticals PLC- (GWPH) and Progenics Pharmaceuticals (PGNX).

Who are Theravance Biopharma's key executives?

Theravance Biopharma's management team includes the folowing people:

Mr. Rick E. Winningham, Chairman & CEO (Age 59)
Mr. Bradford J. Shafer, Exec. VP, Gen. Counsel & Sec. (Age 59)
Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A., Sr. VP of Corp. Devel. & Strategy (Age 46)
Dr. Brett K. Haumann, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 49)
Mr. Vijay Sabesan, Sr. VP of Technical Operations

Who are Theravance Biopharma's major shareholders?

Theravance Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include Campbell & CO Investment Adviser LLC (0.02%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Burton G Malkiel, Donal O'connor, Philip D Worboys, Renee D Gala, Sharathchandra S Hegde and Vijay Sabesan. View Institutional Ownership Trends for Theravance Biopharma.

Which major investors are selling Theravance Biopharma stock?

TBPH stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC. Company insiders that have sold Theravance Biopharma company stock in the last year include Donal O'connor, Sharathchandra S Hegde and Vijay Sabesan. View Insider Buying and Selling for Theravance Biopharma.

Which major investors are buying Theravance Biopharma stock?

TBPH stock was bought by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Theravance Biopharma.

How do I buy shares of Theravance Biopharma?

Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Theravance Biopharma's stock price today?

One share of TBPH stock can currently be purchased for approximately $25.77.

How big of a company is Theravance Biopharma?

Theravance Biopharma has a market capitalization of $1.46 billion and generates $60.37 million in revenue each year. The biopharmaceutical company earns $-215,520,000.00 in net income (profit) each year or ($3.99) on an earnings per share basis. Theravance Biopharma employs 363 workers across the globe.View Additional Information About Theravance Biopharma.

What is Theravance Biopharma's official website?

The official website for Theravance Biopharma is http://www.theravance.com/.

How can I contact Theravance Biopharma?

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]

MarketBeat Community Rating for Theravance Biopharma (NASDAQ TBPH)

Community Ranking:		2.3 out of 5 ( )
Outperform Votes:		265 (Vote Outperform)
Underperform Votes:		299 (Vote Underperform)
Total Votes:		564

MarketBeat's community ratings are surveys of what our community members think about Theravance Biopharma and other stocks. Vote "Outperform" if you believe TBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: What is the outlook for the FAANG stocks?

Your Ultimate Investing Toolkit

Just $1.00 for your first month.